Surgery that carries recurrence rates exceeding 60% depending on technique is the standard of care for a condition affecting roughly 15 million Americans — and that clinical reality is what makes Cloudbreak Pharma’s Phase 3 enrollment closure worth examining closely. The company announced that the final patient has completed the 12-month visit, the primary efficacy endpoint in its randomized, double-masked, vehicle-controlled trial of CBT-001, a topical multi-kinase inhibitor eye drop for pterygium. Topline data is expected in Q3 2026.
The trial design carries its own weight of ambition. Enrollment reached 660 patients across the U.S., China, Australia, New Zealand, and India — a global footprint that Cloudbreak has explicitly structured to support simultaneous commercial filings in multiple markets. The two co-primary endpoints at Month 12 are pterygium lesion size reduction and bothersome ocular symptom score, measured against a vehicle control. That dual-endpoint structure is deliberate: it asks the drug to demonstrate objective anatomical change alongside patient-reported symptom relief, making the approval case harder to dismiss on clinical grounds. Phase 2 data already showed statistically significant reductions in lesion vascularity — a mean change from baseline of -0.8 ± 0.7 in the CBT-001 0.2% arm versus 0.0 ± 0.5 in the vehicle arm at four weeks (P < 0.001) — which gave the Phase 3 design a mechanistic foundation rather than just a clinical hypothesis.
The competitive context matters here. Current pterygium management consists largely of artificial tears, off-label NSAIDs, corticosteroids for symptomatic relief, and surgery for progressive cases. Surgical outcomes are far from reliable, with recurrence rates in bare sclera excision approaching 62.5% for primary pterygium — a figure that underscores why a pharmacologic option capable of reducing or delaying surgical need would represent a genuine shift in management, not a marginal convenience. CBT-001 targets PDGF, VEGF, and FGF receptor tyrosine kinases simultaneously, addressing the angiogenic and fibrogenic drivers of the disease rather than its surface symptoms. The Phase 2 lesion-length data suggest the mechanism translates to measurable tissue-level change, which is the harder bar to clear.
The single metric to watch when topline data arrives in Q3 is the lesion size reduction endpoint — not the symptom score. Regulators and clinicians will scrutinize whether CBT-001 produces durable anatomical regression, because that is the only finding that would credibly position the drug as a disease modifier rather than a sophisticated lubricant. If the lesion endpoint is positive, the argument for shifting pterygium management away from a surgery-first paradigm becomes structurally difficult to ignore.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
